Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUSRE34069 E
Publication typeGrant
Application numberUS 07/481,572
Publication date15 Sep 1992
Filing date16 Feb 1990
Priority date18 Aug 1983
Fee statusPaid
Publication number07481572, 481572, US RE34069 E, US RE34069E, US-E-RE34069, USRE34069 E, USRE34069E
InventorsHubert Koster, Nanda D. Sinha
Original AssigneeBiosyntech Gmbh
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Process for the preparation of oligonucleotides
US RE34069 E
Abstract
The invention relates to a process for the preparation of oligonucleotides by the following steps: reaction of a nucleoside with a phosphine derivative, reaction of the nucleotide derivative thus obtained with a nucleoside bonded to a polymeric carrier, oxidation of the carrier-bound nucleoside-nucleotide thus obtained with formation of phosphotriester groups, blocking of free primary 5'--OH groups, elimination of a protective group from the terminal 5'--OH group, where appropriate single or multiple repetition of the abovementioned steps to introduce further nucleoside phosphate or oligonucleoside phosphate units, and cleavage of the nucleoside-carrier bond and, where appropriate, elimination of all protective groups present in the oligonucleoside phosphates. The phosphine derivative used is a compound of the general formula III ##STR1## in which X and L can react with OH groups of the sugar units in the oligonucleotides, and R3 is a protective group which can be liberated by β-elimination.
Images(5)
Previous page
Next page
Claims(19)
We claim:
1. A process for the preparation of oligonucleotides of the .[.general.]. formula I ##STR13## in which B denotes a nucleoside base, R1 denotes hydrogen, hydroxyl or hydroxyl which is protected by .Iadd., where appropriate, .Iaddend.a removable protective group and n denotes an integer from 1 to 200, comprising the steps of
(a) reacting a nucleoside of the .[.general.]. formula II ##STR14## in which R1 as defined as above, and R2 denotes a removable protective group and B' denotes the nucleotide base B protected by the protective groups which can be eliminated, with a phosphine derivative of the .[.general.]. formula III ##STR15## in which R3 is a protective group which can be eliminated, and X and L are groups which react with hydroxyl groups in the sugar moieties of the nucleotides or nucleosides, in the presence of a base to thereby form a nucleotide phosphite
(b) reacting the nucleotide phosphite obtained in step (a) and represented by the formula IV: ##STR16## in which B', R1, R2, R3 and L are as defined above, with a nucleoside, of the .[.general.]. formula V, bound to a polymeric carrier ##STR17## in which B' and R1 are as defined above and C denotes the polymeric carrier;
(c) oxidizing the carrier-bound nucleoside-nucleotides obtained in step (b) and represented by the formula: ##STR18## in which B', R1, R2, R3 and C are as defined above, with formation of phosphotriester groups,
(d) blocking free primary 5'--OH groups, which have not been reacted in the reaction according to step (b), with permanent protective groups;
(e) eliminating the protective group R2 ;
(f) optionally repeating steps (a) to (e) to introduce further nucleoside phosphate or oligonucleoside phosphate units; and
(g) cleaving the nucleoside carrier bond and optionally eliminating the protective groups present in the oligonucleoside phosphates,
which process comprises using in step (a) as the phosphine derivative of the .[.general.]. formula III a compound in which R3 denotes a group of the formula VII ##STR19## in which the groups Y, which can be identical or different, represent hydrogen, methyl, and/or ethyl and Z represents an electron-attracting group, where, in the phosphine derivative of the formula III, X is chlorine, bromine, CN or SCN and L is CN or SCN, a secondary amino radical of the formula (VIII)
--NR2 4                                           ( VIII)
where the groups R4 are primary, secondary, or tertiary alkyl radicals having .Badd.1-10 carbon atoms, or together form a cycloalkyl radical having 5-7 carbon atoms, which can contain one or two nitrogen, oxygen, or sulfur atoms as hereoatoms, or are imidazole, triazole, tetrazole, 3-nitro-1,2,4-triazole, thiazole, pyrrole, benzotriazole, benzohydroxytriazole, imidazole substituted in the phenyl moiety, triazole substituted in the phenyl moiety, tetrazole substituted in the phenyl moiety, 3-nitro-1,2,4-triazole substituted in the phenyl moiety, thiazole substituted in the phenyl moiety, pyrrole substituted in the phenyl moiety, benzotriazole substituted in the phenyl moiety, or benzohydroxytriazole substituted in the phenyl moiety.
2. The process as claimed in claim 1, in which is used a phosphine derivative of the formula III in which X is chlorine or bromine, and L is a secondary amino radical of the formula (VIII)
--NR2 4                                           (VIII)
where the groups R4 are primary, secondary or tertiary alkyl radicals having 1-10 carbon atoms, or together form a cycloalkyl radical having 5-7 carbon atoms, which can contain one or two nitrogen, oxygen or sulfur atoms as heteroatoms, or are imidazole, triazole, tetrazole, 3-nitro-1,2,4-triazole, thiazole, pyrrole, benzotriazole, benzohydroxytriazole, imidazole substituted in the phenyl moiety, triazole substituted in the phenyl moiety, tetrazole substituted in the phenyl moiety, 3-nitro-1,2,4-triazole substituted in the phenyl moiety, thiazole substituted in the phenyl moiety, pyrrole substituted in the phenyl moiety, benzotriazole substituted in the phenyl moiety, or benzohydroxytrizole substituted in the phenyl moiety.
3. The process as claimed in claim 1 or 2, in which is used a phosphine derivative of the formula (III) in which X is chlorine, L is an N,N-dimethylamino, diethylamino or -diisopropylamino group or N-morpholino group, and R3 is a β-cyanoethyl group.
4. A method of preparing oligonucleotides of the .[.general.]. formula: ##STR20## wherein B is a nucleoside base, R1 is hydrogen, hydroxyl or hydroxyl which is protected by removable nucleoside protective groups, and n denotes an integer from 1 to 200, comprising the steps of:
(a) reacting a nucleotide phosphite represented by the formula: ##STR21## wherein B' is a nucleoside base B protected by .Iadd., where appropriate, .Iaddend.a base protective group which can be eliminated, R1 is as defined above, R2 is 4,4' dimethoxytrityl or 4,4',4" trimethoxytrityl; and L is N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, or N-morpholino, with a nucleoside bound to a polymeric carrier, of the .[.general.]. formula: ##STR22## wherein B' and R1 are as defined above and C represents the polymeric carrier, to produce a carrier bound nucleoside-nucleotide of the formula: ##STR23## wherein B', R1, R2, R3 and C are as defined above; (b) oxidizing the carrier bound nucleoside-nucleotide;
(c) blocking free primary 5'--OH groups, which have not been reacted in the reaction of step (a), with permanent protective groups;
(d) eliminating the protecting group R2 ;
(f) repeating steps (a) to (d) to introduce further nucleoside phosphate units; and
(g) cleaving the nucleoside-carrier bond and optionally eliminating protective groups present in the oligonucleoside phosphates.
5. A method of synthesizing oligonucleotides, comprising the steps of:
(a) coupling a nucleoside β-cyanoethyl-protected phosphoramidite to a carrier-bound nucleoside to produce a carrier bound nucleoside-nucleotide having a phosphite triester linkage;
(b) oxidizing the phosphite triester to form a phosphate triester;
(c) optionally coupling additional nucleoside β-cyanoethyl-protected phosphoramidites to the carrier bound nucleoside-nucleotide and, after each coupling step, oxidizing the resulting phosphite triester to form a phosphate triester, to form a carrier bound polynucleotide;
(d) removing the β-cyanoethyl protecting groups; and
(e) removing the polynucleotide from the carrier.
6. A method of claim 5, wherein the nucleoside β-cyanoethyl phosphoramidite is a nucleoside β-cyanoethyl N,N-dimethylphosphoramidite, N,N-diethylphosphoramidite, .[.N,N-dipropylphosphoramidite.]. .Iadd.N,N-diisopropylphosphoramidite .Iaddend.or N,N-morpholino phosphoramidite.
7. A method of claim 6, wherein the carrier is controlled port glass.
8. A method of claim 7, wherein the β-cyanoethyl protecting group is removed with simultaneous removal of the polynucleotide from the carrier, by concentrated aqueous ammonia.
9. In a method of polynucleotide synthesis, comprising sequentially coupling nucleotide phosphoramidites to produce a polynucleotide, wherein the phosphorus atoms of the nucleotide phosphoramidites are protected by methyl groups, the improvement wherein the phosphorus protecting group are cyanoethyl groups.
10. A method of synthesizing oligonucleotides, comprising the steps of:
a. coupling a nucleoside β-cyanoethyl-protected phosphoramidite to a nucleoside, the nucleoside being bound to a polymeric carrier via an ester bond to produce a carrier-bound nucleoside-nucleotide having a phosphite triester linkage;
b. oxidizing the phosphite triester to form a phosphate triester linkage;
c. sequentially coupling additional nucleoside β-cyanoethyl protected phosphoramidite to the carrier-bound nucleoside-nucleotide, and after each coupling step, oxidizing the resulting phosphite triester linkage to a phosphate triester to produce a carrier-bound polynucleotide;
d. treating the carrier bound polynucleotide with concentrated ammonia to remove the β-cyanoethyl phosphate protecting group and hydrolyzing the ester bond to the carrier to remove the polynucleotide from the carrier.
11. A method of claim 10, wherein the nucleoside β-cyanoethyl phosphoramidite is a nucleoside β-cyanoethyl N,N-dimethylphosphoramidite, N,N-diethylphosphoramidite; .[.N,N-dispropylphosphoramidite.]. .Iadd.N,N-diispropylphosphoramidite .Iaddend.or N,N-morpholino phosphoramidite.
12. A method of claim 10, wherein the carrier is controlled pore glass.
13. A protected nucleotide having the formula: ##STR24## where, B' is a nucleoside base protected .Iadd., where appropriate, .Iaddend.by a base protective group which can be eliminated;
R1 is H, OH, or a hydroxyl group which is protected by a removable nucleoside protective group;
R2 is a removable protective group;
R3 is ##STR25## L is CN, SCN, or NR2 4 ; R4 is a primary, secondary or tertiary alkyl radical having 1-10 carbon atoms, or R2 4 is a cycloalkyl radical having 5-7 carbon atoms or a cycloalkyl radical having 5-7 atoms comprising atoms and one or two nitrogen, oxygen or sulfur atoms as heteroatoms;
Y is H, CH3, or CH2 CH3 ; and Z is a .[.halgen.]. .Iadd.halogen .Iaddend.CN, NO2, phenyl substituted in the o, o' or p positions with a halogen, CN or NO2 radical, phenylthio, phenylsulfoxy, or phenylsulfonyl, where the phenyl radicals, may be substituted in the o, o' or p positions with a halgen, CN or NO2 radical, or where the group ##STR26## may be replaced by CF3, CCl3, or CBr3.
14. A protected nucleotide as in claim 13, wherein Z is CN.
15. A protected nucleotide as in claim 14, wherein R3 l is CH2 --CH2 --CN.
16. A protected nucleotide as in claim 13, wherein R2 is 4,4'-dimethoxytrityl or 4,4"-trimethoxytrityl.
17. A protected nucleotide having the formula: ##STR27## where,
R1 is H, OH, or a hydroxyl group which is protected .Iadd., where appropriate, .Iaddend.by a removable nucleoside protective group;
R2 is 4,4'-dimethoxytrityl or 4,4',4"-trimethoxytrityl;
B' is a nucleoside base protected by a base protective group which can be eliminated
R3 is CH2 --CH2 --CN; and
L is N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino or N-morpholino.
18. A protected nucleotide having the formula: ##STR28## where, R1 is H, OH, or a hydroxyl group which is protected by a protective group selected from the group consisting of trityl groups, acyl groups and silyl ether groups;
R2 is 4,4'-dimethoxytrityl or 4,4',4"-trimethoxytrityl;
B' is a nucleoside base selected from the group consisting of adenine, guanine, cytosine, thymine, uracil and analogs thereof which are protected by acyl groups or Schiff bases;
R3 is CH2 --CH2 --CN; and
L is N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, or N-morpholino.
19. A protected nucleotide of claim 18, wherein .[.R1 .]. .Iadd.R1 .Iaddend. is H and B' is adenine, guanine, cytosine, thymine or uracil wherein the adenine or .[.guanine.]. .Iadd.cytosine .Iaddend.is protected by a benzoyl group and the guanine is protected by an .[.isobutyl.]. .Iadd.isobutyryl .Iaddend.group.
Description
DESCRIPTION

The invention relates to a process for the preparation of oligonucleotides of the general formula I indicated in claim 1. The oligonucleotides prepared according to the invention have defined sequences and can be used as specific primers and probes and are of great importance for the synthesis of complete genes (Arzneimittelforschung 30, 3a, 548, (1980)).

According to the most recent state of the art, oligonucleotides are prepared by either the phosphate or phosphite triester method using polymeric carriers (Nachr. Chem. Tech. Lab. 29, 230 (1981)). In order to be able to construct defined sequences, it is necessary for the individual units (nucleoside or nucleotides) to be provided with suitable protective groups. In this context, base-labile acyl groups are generally used for the protection of the exocyclic amino groups on the heterocyclic nucleobases, and a base-labile ester bond is used to attach the oligonucleotide chain to the polymeric carrier in a customary manner, and acid-labile trityl ether groups are used to protect the primary 5'--OH group. The phosphate protective group used in the phosphate triester method is customarily either the 2-chlorophenyl or the 4-chlorophenyl group, with an ester-type bond, which can only be removed by attack of a base or a nucleophile on the phosphorus atom. This type of step is inherently undesirable since it involves the risk of cleavage of the internucleotide phosphate ester bond. This risk has been greatly reduced by the use of oximate anions (Tetrahedron Lett. 19, 2727 (1978)), although these also attack the phosphorus atom in an undesired manner in the crucial step and, moreover, have the disadvantage that a relatively small amount of desired oligonucleotide is contaminated with every large amounts of involatile salts which are difficult to extract. This not only makes the working up and subsequent purification of the synthesized oligonucleotide difficult but also leads to considerable material losses.

In the phosphite triester method, the methyl group with an ester-type bond is customarily used as the phosphate protective group which can be removed by attack of a nucleophile on the methyl C atom (J. Amer. Chem. Soc. 99, 3526 (I1977)). Since attack on the P atom is avoided, there is likewise avoidance of the risk of cleavage of the internucleotide bond. The nucleophile customarily used is thiophenol/triethylamine, which are unpleasant to manipulate and, moreover, lead to involatile compounds which are difficult to extract and which, as mentioned above, both make work-up difficult and lead to considerable material losses.

Although the actual synthesis of oligonucleotides by the solid phase/phosphite or phosphate triester method takes place very efficiently and rapidly, the preparation of oligonucleotides of defined sequence remains very time-consuming. This is primarily due to the problems of the subsequent work-up and purification which take up a multiple of the actual synthesis time. The process of the invention operates at this point and provides in this connection a crucial technical improvement.

In order to obtain compounds of the formula I indicated in claim 1, ##STR2## in which B denotes a nucleobase, for example adenine (A), guanine (G), cytosine (C), thymine (T) or uracil (U) or their analogs, and R1 denotes hydrogen, hydroxyl or hydroxyl which is protected by the protective groups customary in nucleotide chemistry, and n denotes an integer from 1 to 200, according to the invention a variety of defined reaction steps are carried out, as follows:

(a) Reaction of a nucleoside of the general formula II. ##STR3##

R1 of the general formula II can be hydrogen; in this case the compounds of the formula I are oligodeoxynucleotides. The group R1 can also be hydroxyl or hydroxyl which is, where appropriate, protected by the protective groups customary in nucleotide chemistry. Examples of protective groups of this type are trityl, monomethoxytrityl and dimethoxytrityl, acyl, for example acetyl, benzoyl; tetrahydropyranyl, methoxytetrahydropyranyl, o-nitrobenzyl and silyl ethers, such as, for example, t-butyldiphenylsilyl ethers. A general review of the protective groups customary in nucleotide chemistry is to be found in, for example, Tetrahedron 1981, pages 363-369, Liebigs Ann. Chem. 1978, 839-850, and Nucleic Acids Research, Symposium Series No. 7, 1980, 39-59.

R2 is likewise a protective group customary in nucleotide chemistry according to the above mentioned publications, preferably the acid-labile 4,4'-dimethoxytrityl or 4,4',4"-trimethoxytrityl group. B' can likewise have a protective group customary in nucleotide chemistry according to the above mentioned prior publications.

The nucleoside of the formula II is reacted according to the invention with a phosphine derivative of the general formula III according to claim 1. ##STR4##

In the general formula, X denotes chlorine, bromine, CN or SCN; L denotes chlorine, bromine, CN, SCN or an amino radical of the formula--NR2 4 (formula VIII), where the groups R4 denote primary, or secondary or tertiary alkyl radicals having 1-10 carbon atoms, or together denote a cycloalkyl radical having 5-7 carbon atoms, optionally with alkyl branches, and/or can contain one or two nitrogen, oxygen and/or sulfur atoms as heteroatoms. The group L can also form a reactive heterocyclic radical, the imidazolyl, triazolyl, tetrazolyl, 3-nitro-1,2,4-triazolyl, thiazolyl, pyrrolyl, benzotriazolyl (optionally with substituents in the phenyl moiety) or benzohydroxytriazolyl (optionally with substituents in the phenyl ring) and the like.

R3 is the phosphine derivative of the general formula (III) is, according to the invention, a group of the general formula VII, ##STR5## which can be removed with the aid of bases by β-elimination and in which Y denotes hydrogen, methyl or ethyl. Z represents an electron-attracting group, for example, halogen, such as fluorine, chlorine or bromine, CN or NO2. Z can also denote phenyl, phenylthio, phenylsulfoxy or phenylsulfonyl, it being possible for the phenyl radicals to be substituted in the o,o'-position and/or p-position with halogen, CN or NO2. It is also possible for one of the groups CF3, CCl3 or CBr3 to replace the group ##STR6##

The reaction according to step a takes place in the presence of an organic base.

(b) Reaction of the nucleoside-.[.phosphorous.]. .Iadd.phosphorus .Iaddend.acid derivative, of the formula IV, obtained in step a. ##STR7##

The reaction of the compound according to formula IV is carried out with a nucleoside of the general formula V according to claim 1, which is bound to a polymeric carrier. ##STR8## It is possible to use soluble or insoluble, that is to say crosslinked, polymeric carriers, for example modified silica gel, glass, especially "controlled pore glass", polyester, polyamide, polyvinyl alcohol, polysiloxane, polystyrene or the like. Ester bonds are suitable and preferred for the attachment between the carrier and the nucleoside, including those derived from the levulinyl or β-benzoylpropionyl radical; the latter ester bonds can be cleaved with hydrazine under neutral conditions. The acid-labile trityl ether bond, optionally with substituents in the phenyl rings, is also suitable as a method of attachment, compare Liebigs Ann. Chem. 1974, 959.

(c) Oxidation of the carrier-bond nucleotide-nucleoside, of the general formula VI, obtained in step b. ##STR9##

Oxidation leads to a phosphate group; this can be carried out with, for example, iodine/H2 O, H2 O2 or organic peracids or, in general, by oxidation by introduction of O, S or Se.

(d) Blocking of free primary 5'--OH groups which have not been reacted in the reaction according to step b (in the product of the formula V).

These free hydroxyl groups are blocked with a permanent protective group, for example by reaction with acetic anhydride.

(e) Elimination of the protective groups(s) R2.

The elimination is carried out using, for example, a protonic acid or Lewis acid, such as ZnBr2 or dialkylaltuminum chloride, when R2 represents a trityl group or a methoxy derivative thereof.

(f) Introduction of further nucleoside phosphate or oligonucleoside phosphate units.

Steps a-e can be repeated to introduce at least one nucleoside phosphate moiety. Of course, when oligonucleoside phosphate units are employed, the chains are lengthened by more than one nucleoside phosphate unit.

(g) Elimination of all protective groups.

This elimination can be carried out in such a manner that, using aqueous ammonia, in one step the N-acyl groups on the heterocyclic bases, the ester bond between the oligonucleotide and the carrier (the latter can, where appropriate, also be cleaved with hydrazine under neutral conditions) an the phosphate protective group are eliminated by β-elimination in accordance with the general scheme 1 at the end of the description. An oligonucleotide having only a 5'-terminal trityl protective group is then obtained, and this can be purified directly in a manner known per se, after removal of the volatile base (ammonia), by high-pressure liquid chromatography (HPLC) on reverse phase material.

The intermediates of the general formula IV according to claim 1 are new compounds. They are in the form of very stable compounds which can be prepared in the pure form and are easy to manipulate but nevertheless are very reactive in the sense of forming internucleotide bonds. The use of R3 as a protective group which can be removed by bases via β-elimination makes is possible for the first time to eliminate all the protective groups, apart from the 5'-trityl group, in one step where, in an advantageous manner, by the use of volatile bases the desired oligonucleotide is contaminated with foreign materials to only a very small extent and thus directly afterwards can be purified by reverse phase HPLC due to the hydrophobic 5'-trityl group which is still present.

A further advantage of the process of the invention results from the fact that, due to the removal of the protective group by β-elimination, no attack on the P-atom takes place and thus none of the newly formed internucleotide bonds can be cleaved during the deprotection. Thus, the process of the invention takes very much less time and leads to overall purer products than do the processes hitherto available.

The invention is illustrated in detail below by means of examples, the phosphine derivatives used being those in which R3 is a β-cyanoethyl group. Details of the reaction and physical characteristics of the compounds prepared can be seen in schemes 2 and 3, Table 1, and FIGS. 1-7 at the end of the description.

EXAMPLE 1 Preparation of phosphine derivatives of the general formula III:

β-Cyanoethyl phosphoramidochloridite:

A general summary of the reaction can be seen in scheme 2.

Apart from some improvements, dichloro-β-cyanoethoxyphosphine (1) is prepared as in Can. J. Chem. 58, 2686 (1980):

300 ml of ether and 79.0 g (1 mol) of pyridine are added through a dropping funnel to 137.5 g (1.0 mol) of PCl3 in a three-neck flask; the mixture is cooled to -78 C. under argon. Then a solution of 71.0 g (1 mol) of β-cyanoethanol in 150 ml of dry ether is added dropwise over the course of 1 to 1.5 hours. The cooling bath is removed; stirring is continued at room temperature for a further 3 hours (where necessary, another 300 ml of ether are added in order to ensure better stirrability). The stirrer and dropping funnel are removed under argon; the mixture is stored at 0 C. overnight. The solid salts are removed under argon; the precipitate is washed twice with 75 ml of ether each time. The combined organic phases are concentrated in vacuo; the residue is finally distilled in vacuo; boiling point 70-75 C./0.4 mm Hg.

β-Cyanoethyl phosphoramidochloridite (3):

A solution of 17.2 g (0.1 mol) of β-cyanoethyl phosphorodichloridite (1) in 60 ml of ether is added dropwise, over the course of 1 to 1.5 hours, to a solution of the N-trimethylsilylated secondary amine (0.1 mol) or secondary amine (0.2 mol) in 30 ml of ether at -20 C. under argon. After stirring at room temperature for 20 hours, the amine hydrochloride is removed; the remaining solution is concentrated. The residue is finally distilled in vacuo in a short-path distillation apparatus.

The physical properties of the compounds thus obtained are summarized in Table 1.

FIGS. 1a, 1b and 1c show 31 P NMR spectra of three different β-cyanoethyl phosphoramidochloridites.

The N-morpholine derivative is too unstable to heat for distillation to be possible. Nevertheless, the preparation is so pure that the residue can be used directly for the preparation of the activated nucleoside derivatives. The purity is usually greater than 95% according to the 31 P NMR spectra.

Nucleoside β-cyanoethyl phosphoramidites:

The preparation of the appropriately protected nucleoside β-cyanoethyl phosphoramidites can be seen in scheme 3.

The synthesis is analogy to Tetrahedron Lett. 22, 1859 (1981), with some improvements, provides good yields.

3.0 mmol of the N-protected 5'-dimethoxytritylated deoxynucleoside are dried azeotropically using THF/toluene, dissolved in 15 ml of dry THF, and 12.0 mmol of N,N,N-diisopropylethylamine are added. 6.0 mmol of the β-cyanoethyl phosphoramidochloridite are added dropwise to the solution under argon, with vigorous stirring, over the course of 2 minutes. After a short time (2 to 5 minutes), the amine hydrochloride precipitates out. The suspension is stirred for a further 30 to 40 minutes. The amine hydrochloride is filtered off under argon and thoroughly washed with dry THF (10 to 15 ml). The entire organic phase is concentrated and dissolved in argon-saturated ethyl acetate (100 ml). The organic phase is extracted twice with 50 ml each time of argon-saturated 10% aqueous sodium carbonate solution. The organic phases are dried with sodium sulfate and evaporated under reduced pressure to give a foam. The foam is dissolved in a little ethyl acetate or toluene and precipitated in n-hexane at -78 C. The activated nucleosides are stable for several months when stored at -20 C. under argon.

FIG. 2 shows the 31 P NMR spectrum of one of the activated deoxynucleosides.

Synthesis of d(CGGTACCG)

100 mg of "controlled pore glass" (CPG) loaded with a total of 8 umol of N-isobutyryldeoxyguanine (compare Tetrahedron Lett. 24, 747 (1983)) are consecutively condensed with the 5'-dimethoxytritylated N-acylated β-cyanoethyl N,N-diisopropylphosphoramidites of the deoxynucleosides C, C, A, T, G, G and C, in each case 20 to 25 equivalents of the phosphoramidite in acetonitrile being activated with 75-80 equivalents of sublimed tetrazole. The condensations are complete within 30 minutes at the most; the coupling yield is greater than 94%. After each condensation, oxidation with I2 /H2 O and blocking of unreacted 5'--OH groups with acetic anhydride are carried out. Then the dimethoxytrityl group is eliminated either with 3% trichloroacetic acid in nitromethane/1% methanol or ZnBr2 /nitromethane/1% H2 O.

The overall yield of the protected octanucleotide at the end of all condensation steps is 55% based on carrier-bound deoxyguanosine.

Complete deprotection and cleavage off from the carrier is achieved in one step by reaction of the glass beads with concentrated aqueous ammonia (3 ml) at 50 C. for 16 hours. The glass beads are then thoroughly washed with 50% aqueous methanol (3 times with 3 ml each time). The liquid phase is removed by evaporation (removal of the methanol) and freeze-drying. Then an aliquot is filtered through a millipore filter and purified by HPLC or RP 18 as can be seen in FIG. 3.

The fractions which contain the 5'-dimethoxytritylated oligonucleotide are collected; the volatile buffer is removed in a rotary evaporator in vacuo, 1 ml of 80% strength acetic acid is added to the residue. After 45 minutes at room temperature, the acetic acid is removed by freeze-drying.

The material thus obtained is phosphorylated in the customary manner (Liebigs Ann. Chem. 1978, 982) with T4-polynucleotide kinase and γ-32 P-ATP. The resulting product is characterized by polyacrylamide gel electrophoresis comparing with a homo-oligo-dT chain length standard (Nucleic Acids Res. 6, 2096 (1979), FIG. 4) and by sequencing according to FIG. 5 (Liebigs Ann. Chem. 1978, 982).

FIGS. 6a to 6c show the results (HPLC, gel electrophoresis, sequencing) of the synthesis of d(GGGATCCC) using the nucleoside β-cyanoethyl N,N-dimethylphosphoramidites, FIGS. 6a to 6c show the results (HPLC, g, electrophoresis, sequencing) of the synthesis of d(GGGATATCCC) using the nucleoside β-cyanoethyl N,N-morpholinophosphoramidites.

The results given in FIGS. 3, 6a and 7a were obtained by using a gradient from 10 to 25 vol. % CH3 CN, 5 min, and 25 to 29 vol. % CH3 CN, 30 min, in 0.1M triethylammonium acetate at pH 7.0. ##STR10##

                                  TABLE 1__________________________________________________________________________Physical data of β-cyanoethyl phosphoramidochloridites    3a             3b             3cCompound L = N,N-dimethylamino                   L = N,N-diisopropylamino                                  L = N-morpholino__________________________________________________________________________Boiling point    90-92/0.6 nm                   103-5/0.06 nm                                  --Chemical shift.sup.(2)    175.97 ppm     179.82 ppm     168.22 ppmin 31 P NMR inCH3 CNChemical shift in    4.01, 4.17(2t, POCH2, 2H)                   4.02, 4.2(2t, POCH2, 2H)                                  3.96, 4.1(2t, POCH2, 2H)1 H NMR in ppm    2.71(t, CH2CN, 2H)                   3.8(m, N(CH)2, 2H)                                  3.67(t, O(CH2)2, 4H)    2.7(d, N(CH3)2, 6H)                   2.77(t, CH2 CH, 2H)                                  3.17(m, PN(CH2)2, 4H)                   1.29(d, NCH(CH3)2, 12H)                                  2.74(t, CH2CN 2, 2H) Mass spectrum                    ##STR11##                                   ##STR12##    (Cl), 136(C2 H6 N), 110                   (Cl), 166(C3 H4 NO),                                  (Cl), 152(C3 H4 NO),    (C3 H4 NO)                   136(C6 H14 N)                                  136(C4 H8 O)__________________________________________________________________________ .sup.(1) The crude product after removal of amine hydrochloride and compounds volatile under high vacuum at room temperature has a purity of 93-95% according to the 31 P NMR spectrum .sup.(2) The chemical shifts are determined in acetoned6 with 80% strength H3 PO4 as the external standard.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4310662 *26 Dec 197912 Jan 1982Genentech, Inc.Nucleosidic phosphorylating agent and methods
US4415732 *27 Mar 198115 Nov 1983University Patents, Inc.Phosphoramidite compounds and processes
US4419509 *24 Aug 19816 Dec 1983Eli Lilly And CompanyProcess for de-cyanoethylating blocked nucleotides
US4458066 *24 Mar 19813 Jul 1984University Patents, Inc.Process for preparing polynucleotides
US4476301 *22 Jun 19829 Oct 1984Centre National De La Recherche ScientifiqueOligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
US4500707 *16 Mar 198219 Feb 1985University Patents, Inc.Nucleosides useful in the preparation of polynucleotides
US4591614 *30 Apr 198427 May 1986The Johns Hopkins UniversityPreparation of oligodeoxyribonucleoside alkyl or arylphosphonates
US4605735 *9 Feb 198412 Aug 1986Wakunaga Seiyaku Kabushiki KaishaNon radioactive affinity probe for nucleic acids; immunoassay; genetic engineering
EP0040099A1 *12 May 198118 Nov 1981ens BIO LOGICALS INC.Polynucleotide synthesis
EP0061746A1 *26 Mar 19826 Oct 1982University Patents, Inc.Phosphoramidite compounds and their use in producing oligonucleotides
EP0064796A2 *10 May 198217 Nov 1982Unilever N.V.Phosphorylating agent and process for the phosphorylation of organic hydroxyl compounds
EP0090789A1 *24 Mar 19835 Oct 1983Monsanto CompanyChemical DNA synthesis
EP0131993A2 *29 Jun 198423 Jan 1985Stichting Katholieke UniversiteitPhosphorylating agent; a process for the preparation thereof; a process for phosphorylating an organic hydroxyl or amine compound
Non-Patent Citations
Reference
1 *Beaucage and Caruthers (1981) Tet. Lett. 22:1859 1862.
2Beaucage and Caruthers (1981) Tet. Lett. 22:1859-1862.
3 *Caruthers, M. H., Science 230:281 (1985).
4Clesen et al., "Tetrahedron Letters", vol. 25, No. 12, pp. 1307-1310, 1984.
5 *Clesen et al., Tetrahedron Letters , vol. 25, No. 12, pp. 1307 1310, 1984.
6 *Gao, X. et al. Nucleic Acids Research 13(2):573 (1985).
7 *H. Koster et al., Nucleic Acids Research Symposium Series No. 7 (1980) pp. 39 61.
8H. Koster et al., Nucleic Acids Research Symposium Series No. 7 (1980) pp. 39-61.
9Lelsinger et al., "Jour. of the Amer. Chem. Soc." vol. 98, No. 12, Jun. 1976, pp. 3655-3661.
10 *Lelsinger et al., Jour. of the Amer. Chem. Soc. vol. 98, No. 12, Jun. 1976, pp. 3655 3661.
11Marugg et al., "Recl. Trav. Chim. Pays-Bas" vol. 103, pp. 97-98, 1984.
12 *Marugg et al., Recl. Trav. Chim. Pays Bas vol. 103, pp. 97 98, 1984.
13Narang, "Tetrahedron", vol. 39, No. 1, pp. 3-22, 1983.
14 *Narang, Tetrahedron , vol. 39, No. 1, pp. 3 22, 1983.
15 *Ogilvie, K. K. et al., Can J. Chem 58:2686 (1980).
16 *Urdea, M. S. et al. Nucleic Acids Research Symposium Ser. 16 (1985) pp. 257 260.
17Urdea, M. S. et al. Nucleic Acids Research Symposium Ser. 16 (1985) pp. 257-260.
18 *V. Amarnath and A. D. Broom, Chemical Reviews 77(2)183 (1977).
19 *Zon, G. et al., Nucleic Acids Research 13(22):8181 (1985).
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US5428149 *14 Jun 199327 Jun 1995Washington State University Research FoundationReacting vinyl and aryl stannanes with 2'-deoxy-5-halo-uridine
US5510476 *7 Jul 199423 Apr 1996Isis Pharmaceuticals, Inc.Carbocation scavenging during oligonucleotide synthesis
US5633361 *21 Mar 199527 May 1997Washington State University Research FoundationOligonucleotides
US5714597 *8 Mar 19963 Feb 1998Isis Pharmaceuticals, Inc.Use of carbocation scavenger during oligonucleotide synthesis
US5734041 *20 Oct 199531 Mar 1998Mcgill UniversityPreparation of chiral phosphorothioate oligomers
US5760209 *3 Mar 19972 Jun 1998Isis Pharmaceuticals, Inc.Protecting group for synthesizing oligonucleotide analogs
US5783690 *18 Sep 199721 Jul 1998Isis Pharmaceuticals, Inc.Phosphitylating agents for preparing nucleoside phosphoramidites
US5902881 *3 Mar 199711 May 1999Isis Pharmaceuticals, Inc.Reagent useful for synthesizing sulfurized oligonucleotide analogs
US61691776 Nov 19982 Jan 2001Isis Pharmaceuticals, Inc.Processes for the synthesis of oligomeric compounds
US617221727 Dec 19969 Jan 2001Isis Pharmaceuticals Inc.Method of synthesizing phosphorothioate oligonucleotides
US620781912 Feb 199927 Mar 2001Isis Pharmaceuticals, Inc.Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
US623922016 Jul 199929 May 2001Isis Pharmaceuticals, Inc.Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis
US627472523 Oct 199814 Aug 2001Isis Pharmaceuticals, Inc.Providing compound having a hydroxyl group; reacting with phosphitylating reagent in the presence of a pyridinum salt in a solvent under conditions of time, temperature and pressure to yield phosphitylated compound
US627733418 May 199921 Aug 2001Isis Pharmaceuticals, Inc.Chemical synthesis apparatus employing a droplet generator
US62911705 Apr 199918 Sep 2001Board Of Trustees Of Leland Stanford UniversityComplementary deoxyribonucleic acid is synthesized by rna using a complementary primer linked to a rna polymerase promoter, anti-sense rna is transcribed from the cdna when rna polymerase binds the promoter region; diagnosis/forensic
US629466426 May 199525 Sep 2001Isis Pharmaceuticals, Inc.Preparing oligonucleotide blocks having common subsequences, phospitylating, and performing solid phase synthesis (sps) to form target oligonucleotides wherein the synthons used in sps comprise phosphitylated oligonucleotide blocks
US63264788 Jul 19984 Dec 2001Isis Pharmaceuticals, Inc.Oligonucleotides and medical diagnosis, metabolism
US63264794 Jan 19994 Dec 2001Boston Probes, Inc.Synthetic polymers and methods, kits or compositions for modulating the solubility of same
US633543424 Mar 19991 Jan 2002Isis Pharmaceuticals, Inc.,Nucleosidic and non-nucleosidic folate conjugates
US63354377 Sep 19981 Jan 2002Isis Pharmaceuticals, Inc.Methods for the preparation of conjugated oligomers
US633543911 Jun 19981 Jan 2002Isis Pharmaceuticals, Inc.Method of preparing phosphoramidites
US63997568 Jul 19994 Jun 2002Isis Pharmaceuticals, Inc.Process for the synthesis of oligomeric compounds
US639976517 Mar 19994 Jun 2002Isis Pharmaceuticals, Inc.Dealkylation using acid solution
US63998311 Dec 19994 Jun 2002Isis Pharmaceuticals, Inc.Thiodicarbonic acid diester polysulfide
US64037818 Jan 200111 Jun 2002Isis Pharmaceuticals, Inc.Method of synthesizing phosphorothioate oligonucleotides
US64141357 Jul 19992 Jul 2002Isis Pharmaceuticals, Inc.Phosphonylation of alkylnucleoside with bis(trimethylsilyl)phosphonite in base presence; concentration; adding methanol solvent; nuclease resistance; hybridization
US644094314 Jul 199927 Aug 2002Isis Pharmaceuticals, Inc.Mimic and/or modulate the activity of wild-type nucleic acids; the 5' and the 3'-terminal internucleoside linkages are chirally sp and internal internucleoside linkages are chirally rp; resistant to nuclease degradation; psoriasis
US64411616 Nov 200027 Aug 2002Gilead Sciences, Inc.Urea nucleosides as therapeutic and diagnostic agents
US646218429 Nov 20008 Oct 2002Isis Pharmaceuticals, Inc.Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
US64656289 Apr 199915 Oct 2002Isis Pharmaceuticals, Inc.Process for the synthesis of oligomeric compounds
US647621618 Oct 19965 Nov 2002Mcgill UniversityPreparation of phosphorothioate oligomers
US652177511 Dec 200118 Feb 2003Isis Pharmaceuticals, Inc.Genetically engineered oligonucleotides for use as diagnostic and therapeutic tools in gene therapy
US652863116 Jun 19984 Mar 2003Isis Pharmaceuticals, Inc.Folates are conjugated to an oligonucleotide including at the 2'-, 3'-, 5'-, nucleobase and internucleotide linkage sites; improved transfer across cellular membranes; regioselective synthesis
US653159024 Apr 199811 Mar 2003Isis Pharmaceuticals, Inc.Processes for the synthesis of oligonucleotide compounds
US65346397 Jul 200018 Mar 2003Isis Pharmaceuticals, Inc.Guanidinium functionalized oligonucleotides and method/synthesis
US655863321 Sep 19946 May 2003Isis Pharmaceuticals, Inc.Utilizing jetting droplet generation and direction techniques; easy, economical, efficient, high yield
US65934667 Jul 199915 Jul 2003Isis Pharmaceuticals, Inc.Guanidinium functionalized nucleotides and precursors thereof
US65968571 Dec 199922 Jul 2003Mcgill UniversityPreparation of phosphorothioate oligomers
US66000326 Aug 199929 Jul 2003Isis Pharmaceuticals, Inc.Compound for use in the treatment of viral, protozoan and parasitic infections
US661083716 Mar 200026 Aug 2003Isis Pharmaceuticals, Inc.Preparation of an oligonucleotide compound of given formula by reacting with given compounds, followed by oxidation or sulfurization
US66108426 May 199926 Aug 2003Isis Pharmaceuticals, Inc.Removing hydroxyl protecting group from compound of given formula and treating with another compound; wide range of diagnostic and therapeutic uses
US66390617 Jul 199928 Oct 2003Isis Pharmaceuticals, Inc.C3′-methylene hydrogen phosphonate oligomers and related compounds
US664237312 Dec 20024 Nov 2003Isis Pharmaceuticals, Inc.Activators for oligonucleotide synthesis
US667391211 Apr 20026 Jan 2004Isis Pharmaceuticals, Inc.2′-O-aminoethyloxyethyl-modified oligonucleotides
US66774718 Nov 200213 Jan 2004Isis Pharmaceuticals, Inc.Intermediates for the synthesis of oligonucleotide analogues
US676229823 Feb 200113 Jul 2004The United States Of America As Represented By The Department Of Health And Human ServicesThermolabile phosphorus protecting groups, associated intermediates and methods of use
US677044230 Nov 20013 Aug 2004Boston Probes, Inc.Methods for modulating the solubility of synthetic polymers
US678098917 Jan 200324 Aug 2004Isis Pharmaceuticals, Inc.Hybrid oligonucleotide
US679450222 Mar 200221 Sep 2004Isis Pharmaceuticals, Inc.Half-life is determined for deprotection of 5'-oh protecting group at the 5'-terminus of an oligonucleotide post-synthesis
US680075111 Apr 20025 Oct 2004Isis Pharmaceuticals, Inc.Reagent and process for protecting nucleoside hydroxyl groups
US68183956 Nov 200016 Nov 2004California Institute Of TechnologyFor automatic high speed/throughput analysis without size-separating dna fragments on polyacrylamide gel electrophoresis
US682208816 Jul 200223 Nov 2004Isis Pharmaceuticals, Inc.Synthesis of oligonucleotides on solid support
US682533830 Mar 200130 Nov 2004Isis Pharmaceuticals, Inc.Selective functionalization of oligonucleotides with conjugate groups without the need for post-synthetic labeling; solid phase synthesis; deblocking an acid labile hydroxyl group and reacting with a phosphoramidite
US68469228 Nov 200025 Jan 2005Isis Pharmaceuticals, Inc.Activators for oligonucleotide synthesis
US68615149 Oct 20011 Mar 2005Isis Pharmaceuticals, Inc.The folate can be attached via the alpha - or gamma -carboxylate, optionally through a linking group.
US686151824 Sep 20021 Mar 2005Mcgill UniversityHybrid oligonucleotide
US686729412 Nov 199915 Mar 2005Isis Pharmaceuticals, Inc.Design and synthesis of nuclease resistant gapped oligonucleotides which are useful for therapeutics, diagnostics and as research reagents ; are also capable of modulating the activity of DNA and RNA
US691134518 Jul 200128 Jun 2005California Institute Of TechnologyMethods and apparatus for analyzing polynucleotide sequences
US69141389 Aug 20025 Jul 2005Gilead Sciences, Inc.Urea nucleosides as therapeutic and diagnostic agents
US691943710 Jun 199919 Jul 2005Isis Pharmaceuticals, Inc.A prodrug forms of oligonucleotides, able releasing the oligonucleotide by intercellular enzymes, a protecting groups comprising a nucleoside ribose esters, or binding to polyamides, or polyethers, or a solid supports
US696504116 Feb 200015 Nov 2005The United States Of America As Represented By The Department Of Health And Human ServicesN-acylphosphoramidites and their use in oligonucleotide synthesis
US696724724 Jul 200222 Nov 2005Isis Pharmaceuticals, Inc.Deprotection of phosphorus in oligonucleotide synthesis
US697486518 Dec 200213 Dec 2005Isis Pharmaceuticals, Inc.C3′ -methylene hydrogen phosphonate oligomers and related compounds
US700200612 Feb 200321 Feb 2006Isis Pharmaceuticals, Inc.reacting a nucleoside with a protecting reagent and activator to produce a regioselectively protected oligonucleoside; lutidine activator improves selectivity; for automatic synthesis of primers, probes and antiseisure agents
US703023025 Oct 200218 Apr 2006Isis Pharmaceuticals, Inc.Dissolving of raw materials; solvent extraction
US704181620 Jan 20049 May 2006Isis Pharmaceuticals, Inc.solid phase deprotection of cyanoethyl groups on the phosphorothioate backbone of an oligonucleotide with an amine deprotecting agent (triethylamine); cleaving the oligonucleotide from the support; minimal acrylonitrile nucleobase adduct formation; by-product inhibition
US704910215 Nov 200023 May 2006Board Of Trustees Of Leland Stanford UniversityMulti-gene expression profile
US705706211 Apr 20026 Jun 2006Isis Pharmaceuticals, Inc.Dissolving a crude phosphorodiamidite in an apolar organic solvent, contacting the non-polar organic solvent with a polar phase comprising a polar organic solvent to remove impurities; removing the nonpolar solvent; antisense agents
US707456324 Feb 200311 Jul 2006Sequenom, Inc.Mass spectrometric methods for detecting mutations in a target nucleic acid
US712594519 Sep 200324 Oct 2006Varian, Inc.Chromatographic separation of a mixture of analytes by using an absorber, a halogenated polymers of vinyl aromatic monomers comprising styrene and divinylbenzene; separating polar analytes from nonpolar analytes; separating labeled nucleic acids from unlabeled nucleic acids
US716956024 May 200430 Jan 2007Helicos Biosciences CorporationShort cycle methods for sequencing polynucleotides
US716991631 Mar 200330 Jan 2007Isis Pharmaceuticals, Inc.Chloral-free DCA in oligonucleotide synthesis
US718682228 Dec 20046 Mar 2007Isis Pharmaceuticals, Inc.Process for the synthesis of oligomeric compounds
US719923614 Sep 20043 Apr 2007Isis Pharmaceuticals, Inc.Deprotecting nucleotides having phosphotriester or phosphorodithioate linkages and at least one cyanoethyl protecting group by reaction with an amine deprotecting agent; solid phase synthesis
US722054930 Dec 200422 May 2007Helicos Biosciences CorporationStabilizing a nucleic acid for nucleic acid sequencing
US722701628 Dec 20045 Jun 2007Isis Pharmaceuticals, Inc.Process for the synthesis of oligomeric compounds
US7227017 *5 Jun 20035 Jun 2007Avecia LimitedLarge-scale synthesis of phosphorothioate oligonucleotides for use in phamaceutical industry and rational drug design/screening
US7273933 *26 Feb 199825 Sep 2007Isis Pharmaceuticals, Inc.Methods for synthesis of oligonucleotides
US72765992 Jun 20042 Oct 2007Isis Pharmaceuticals, Inc.Oligonucleotide synthesis with alternative solvents
US729751812 Mar 200220 Nov 2007California Institute Of TechnologyMethods and apparatus for analyzing polynucleotide sequences by asynchronous base extension
US73483912 Sep 200525 Mar 2008Isis Pharmaceuticals, Inc.solid support media for use in oligomer synthesis, methods of producing the media, and methods of using the media. In some embodiments, the processes of the invention comprise (a) providing an organic phase comprising an olefin monomer, a cross-linker, a functionalizing reagent and an initiator;
US73550373 Dec 20028 Apr 2008The United States Of America As Represented By The Department Of Health And Human ServicesThermolabile hydroxyl protecting groups and methods of use
US73975468 Mar 20068 Jul 2008Helicos Biosciences CorporationSystems and methods for reducing detected intensity non-uniformity in a laser beam
US739984527 Jan 200715 Jul 2008Isis Pharmaceuticals, Inc.For modulating gene expression pathways, including those relying on mechanisms of action such as RNaseH, RNAi and dsRNA enzymes, as well as other antisense mechanisms based on target degradation or target occupancy; of therapeutic, diagnostics, and research applications; nuclease resistance
US741978711 May 20062 Sep 2008Sequenom, Inc.Amplifying, ionizing and volatilizing for determining presence of nucleotide sequence; matrix-assisted laser desorption, ionization time-of-flight; genetic disorders
US742767522 Aug 200523 Sep 2008Isis Pharmaceuticals, Inc.Compounds and methods for the characterization of oligonucleotides
US746244914 May 20049 Dec 2008California Institute Of TechnologyUsing immobilized microfluidic chip as tool in sequencing of preferential nucleotide sequences; high throughput assay
US74767346 Dec 200513 Jan 2009Helicos Biosciences CorporationNucleotide analogs
US748212028 Jan 200527 Jan 2009Helicos Biosciences CorporationMethods and compositions for improving fidelity in a nucleic acid synthesis reaction
US749149826 Oct 200617 Feb 2009Helicos Biosciences CorporationShort cycle methods for sequencing polynucleotides
US754768410 May 200716 Jun 2009Isis Pharmaceuticals, Inc.(1R,3R,4R,7S)-7-[2-Cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(S)-(4,4'-dimethoxytrityl)oxy-ethyl]-3-(uracil-1-yl)-2,5-dioxa-bicyclo[2.2.1]heptane; useful for enhancing properties of oligomeric compounds including for example enhanced nuclease resistance
US756968610 May 20074 Aug 2009Isis Pharmaceuticals, Inc.Compounds and methods for synthesis of bicyclic nucleic acid analogs
US763556225 May 200522 Dec 2009Helicos Biosciences CorporationLabelling, hybridization, solid phase synthesis; attaching nucleic acid molecules via covalent linkages to reactive chemical groups on surface, blocking with solution comprising potassium phosphate, reacting with label, rinsing, then analyzing
US76455965 May 200412 Jan 2010Arizona Board Of RegentsPolymerase chain reactions; exonucleases; microfluidics
US766659326 Aug 200523 Feb 2010Helicos Biosciences CorporationSingle molecule sequencing of captured nucleic acids
US76668549 Dec 200823 Feb 2010Isis Pharmaceuticals, Inc.Bis-modified bicyclic nucleic acid analogs
US769590220 Feb 200213 Apr 2010Isis Pharmaceuticals, Inc.Contacting test solution containing Rna and enzyme; hybridization
US770070617 Dec 200720 Apr 2010Isis Pharmaceuticals, Inc.solid support media for use in oligomer synthesis, methods of producing the media, and methods of using the media. In some embodiments, the processes of the invention comprise (a) providing an organic phase comprising an olefin monomer, a cross-linker, a functionalizing reagent and an initiator;
US774145729 May 200822 Jun 2010Isis Pharmaceuticals, Inc.6-modified bicyclic nucleic acid analogs
US775013119 Mar 20096 Jul 2010Isis Pharmaceuticals, Inc.(1R,3R,4R,7S)-7-[2-Cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(S)-(4,4'-dimethoxytrityl)oxy-ethyl]-3-(uracil-1-yl)-2,5-dioxa-bicyclo[2.2.1]heptane; useful for enhancing properties of oligomeric compounds including nuclease resistance
US775906522 May 200820 Jul 2010Sequenom, Inc.Digesting a target nucleic acid molecule; capturing digested fragments on a solid support that containing oligonucleotides complementary, detecting hybrids and molecular weight of captured fragments by mass spectrometry to identify mutations; Fast and highly accurate
US775948029 Jan 200720 Jul 2010Isis Pharmaceuticals, Inc.Chloral-free DCA in oligonucleotide synthesis
US78121494 Nov 200312 Oct 2010Isis Pharmaceuticals, Inc.Comprises nucleotide sequences for use in gene expression inhibition, viral defense, transposon silencing and treatment of metabolic disorders; antisense agents
US78840867 Sep 20058 Feb 2011Isis Pharmaceuticals, Inc.identifying siRNA and double-stranded RNA compounds, having bioactivity in vivo; nucleosides
US789734513 Feb 20091 Mar 2011Helicos Biosciences CorporationShort cycle methods for sequencing polynucleotides
US79816049 Feb 200519 Jul 2011California Institute Of TechnologyMethods and kits for analyzing polynucleotide sequences
US80221935 May 201020 Sep 2011Isis Pharmaceuticals, Inc.6-modified bicyclic nucleic acid analogs
US803046731 Mar 20104 Oct 2011Isis Pharmaceuticals, Inc.5′-modified bicyclic nucleic acid analogs
US808874614 Jan 20103 Jan 2012Isis Pharmaceuticals, Inc.Bis-modified bicyclic nucleic acid analogs
US808890415 Aug 20083 Jan 2012Isis Pharmaceuticals, Inc.Tetrahydropyran nucleic acid analogs
US813833011 Sep 200720 Mar 2012Sigma-Aldrich Co. LlcSolid phase synthesis via deblocking immobilized nucleoside, then coupling acyl protected nucleoside phosphoramidite
US815360220 May 199910 Apr 2012Isis Pharmaceuticals, Inc.Composition and methods for the pulmonary delivery of nucleic acids
US81880597 May 200729 May 2012Isis Pharmaceuticals, Inc.Compounds and methods for modulating expression of GCGR
US826898023 Sep 201118 Sep 2012Isis Pharmaceuticals, Inc.5′-modified bicyclic nucleic acid analogs
US82782831 Jul 20082 Oct 2012Isis Pharmaceuticals, Inc.6-disubstituted or unsaturated bicyclic nucleic acid analogs
US827842522 May 20082 Oct 2012Isis Pharmaceuticals, Inc.N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US82784266 Jun 20082 Oct 2012Isis Pharmaceuticals, Inc.Carbocyclic bicyclic nucleic acid analogs
US836223215 Sep 201029 Jan 2013Isis Pharmaceuticals, Inc.Compounds and methods for modulating expression of SGLT2
US836223426 Mar 200729 Jan 2013Archemix LlcSolid support reagents for synthesis
US83729677 May 200712 Feb 2013Isis Pharmaceuticals, Inc.Compounds and methods for modulating expression of GCCR
US83949473 Mar 200412 Mar 2013Isis Pharmaceuticals, Inc.has a plurality of modified ribofuranosyl nucleosides at defined locations; comprise double stranded constructs wherein one of the strands capable of hybridizing to a nucleic acid target
US842637819 Mar 200923 Apr 2013Isis Pharmaceuticals, Inc.Oligomeric compounds comprising tricyclic nucelosides and methods for their use
US84408031 Dec 201114 May 2013Isis Pharmaceuticals, Inc.Tetrahydropyran nucleic acid analogs
US850180523 Sep 20096 Aug 2013Isis Pharmaceuticals, Inc.Substituted alpha-L-bicyclic nucleosides
US85306406 Feb 200910 Sep 2013Isis Pharmaceuticals, Inc.Bicyclic cyclohexitol nucleic acid analogs
US85363201 Feb 201017 Sep 2013Isis Pharmaceuticals, Inc.Tetrahydropyran nucleic acid analogs
US854655621 Nov 20081 Oct 2013Isis Pharmaceuticals, IncCarbocyclic alpha-L-bicyclic nucleic acid analogs
US85694744 Mar 200529 Oct 2013Isis Pharmaceuticals, Inc.Double stranded constructs comprising one or more short strands hybridized to a longer strand
US86041834 Nov 200310 Dec 2013Isis Pharmaceuticals, Inc.Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US860419223 Sep 200910 Dec 2013Isis Pharmaceuticals, Inc.Cyclohexenyl nucleic acids analogs
US863697815 Jun 200928 Jan 2014The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesCyclized NGR peptide compounds, compositions, and methods of their use
US86738717 May 200718 Mar 2014Isis Pharmaceuticals, Inc.Compounds and methods for modulating expression ApoB
US87037288 Sep 200422 Apr 2014Isis Pharmaceuticals, Inc.Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US879643717 Apr 20135 Aug 2014Isis Pharmaceuticals, Inc.Tetrahydropyran nucleic acid analogs
USRE39464 *24 Aug 20049 Jan 2007Isis Pharmaceuticals Inc.Oligonucleolotides having site specific chiral phosphorothioate internucleoside linkages
EP2053406A216 Jul 200229 Apr 2009caprotec bioanalytics GmbHCapture compounds, collections thereof and methods for analyzing the proteome and complex compositions
EP2314594A127 Jan 200727 Apr 2011Isis Pharmaceuticals, Inc.6-modified bicyclic nucleic acid analogs
EP2332951A227 Jan 200715 Jun 2011ISIS Pharmaceuticals, Inc.6-modified bicyclic nucleic acid analogs
EP2708541A115 Nov 200419 Mar 2014Isis Pharmaceuticals, Inc.5,6-dihydroxy-isoindole derivatives as linkers for oligomer solid phase synthesis
WO2007134181A210 May 200722 Nov 2007Isis Pharmaceuticals Inc5'-modified bicyclic nucleic acid analogs
WO2008150729A222 May 200811 Dec 2008Isis Pharmaceuticals IncN-substituted-aminomethylene bridged bicyclic nucleic acid analogs
WO2010064146A22 Dec 200910 Jun 2010Chiralgen, Ltd.Method for the synthesis of phosphorus atom modified nucleic acids
WO2010090969A11 Feb 201012 Aug 2010Isis Pharmaceuticals, Inc.Tetrahydropyran nucleic acid analogs
WO2011005860A27 Jul 201013 Jan 2011Alnylam Pharmaceuticals, Inc.5' phosphate mimics
WO2011005861A17 Jul 201013 Jan 2011Alnylam Pharmaceuticals, Inc.Oligonucleotide end caps
WO2011017521A25 Aug 201010 Feb 2011Isis Pharmaceuticals, Inc.Bicyclic cyclohexose nucleic acid analogs
WO2011085102A16 Jan 201114 Jul 2011Isis Pharmaceuticals, Inc.Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011094580A228 Jan 20114 Aug 2011Alnylam Pharmaceuticals, Inc.Chelated copper for use in the preparation of conjugated oligonucleotides
WO2011115818A110 Mar 201122 Sep 2011Isis Pharmaceuticals, Inc.5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011139695A226 Apr 201110 Nov 2011Isis Pharmaceuticals, Inc.Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
WO2011139699A226 Apr 201110 Nov 2011Isis Pharmaceuticals, Inc.5' modified nucleosides and oligomeric compounds prepared therefrom
WO2011139702A226 Apr 201110 Nov 2011Isis Pharmaceuticals, Inc.Modified nucleosides and oligomeric compounds prepared therefrom
WO2011139911A229 Apr 201110 Nov 2011Isis Pharmaceuticals, Inc.Lipid formulated single stranded rna
WO2011163121A120 Jun 201129 Dec 2011Alnylam Pharmaceuticals, Inc.Multifunctional copolymers for nucleic acid delivery
Classifications
U.S. Classification536/25.34, 536/26.5, 536/25.3, 987/189, 536/26.71
International ClassificationC07H21/00
Cooperative ClassificationC07H21/00
European ClassificationC07H21/00
Legal Events
DateCodeEventDescription
9 Aug 1999FPAYFee payment
Year of fee payment: 12
9 Sep 1998ASAssignment
Owner name: PROLIGO L.L.C., COLORADO
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEXSTAR PHARMACEUTICALS, INC.;REEL/FRAME:009436/0625
Effective date: 19980815
15 Apr 1998ASAssignment
Owner name: NEXSTAR PHARMACEUTICALS, INC., COLORADO
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PERSEPTIVE BIOSYSTEMS, INC.;REEL/FRAME:009097/0853
Effective date: 19980122
19 Mar 1996CCCertificate of correction
7 Aug 1995FPAYFee payment
Year of fee payment: 8
29 Nov 1994RRRequest for reexamination filed
Effective date: 19940610
14 Nov 1994ASAssignment
Owner name: PERSEPTIVE BIOSYSTEMS, INC., MASSACHUSETTS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MILLIPORE INVESTMENT HOLDINGS LIMITED;REEL/FRAME:007189/0912
Effective date: 19941102
5 Apr 1994RRRequest for reexamination filed
Effective date: 19940112
17 Feb 1994ASAssignment
Owner name: MILLIPORE INVESTMENT HOLDINGS LTD., DELAWARE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MILLIPORE CORPORATION;REEL/FRAME:006862/0716
Effective date: 19931214
17 Aug 1993RRRequest for reexamination filed
Effective date: 19930701
19 Apr 1993ASAssignment
Owner name: MILLIPORE CORPORATION, MASSACHUSETTS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:BIOSYNTECH GMBH;REEL/FRAME:006495/0624
Effective date: 19930329